open access

Vol 5, No 4 (2009)
Case report
Published online: 2009-07-30
Get Citation

Metastatic breast cancer in young woman: capecitabine monotherapy after failure of the targeted therapy - a case report

Beata Kordela
Onkol. Prak. Klin 2009;5(4):158-162.

open access

Vol 5, No 4 (2009)
CASE REPORT
Published online: 2009-07-30

Abstract

Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women with metastatic HER2-positve breast cancer progressing during trastuzumab and lapatinib treatment. This is a case report concerning anthracycline- and taxane-resistant advanced breast cancer in a young woman and the treatment after failure of the targeted therapy.

Abstract

Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women with metastatic HER2-positve breast cancer progressing during trastuzumab and lapatinib treatment. This is a case report concerning anthracycline- and taxane-resistant advanced breast cancer in a young woman and the treatment after failure of the targeted therapy.
Get Citation

Keywords

metastatic breast cancer; HER2-targeted therapy; capecitabine

About this article
Title

Metastatic breast cancer in young woman: capecitabine monotherapy after failure of the targeted therapy - a case report

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 4 (2009)

Article type

Case report

Pages

158-162

Published online

2009-07-30

Bibliographic record

Onkol. Prak. Klin 2009;5(4):158-162.

Keywords

metastatic breast cancer
HER2-targeted therapy
capecitabine

Authors

Beata Kordela

References (24)
  1. Sidoni A, Cavaliere A, Bellezza G, et al. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003; 12(4): 247–250.
  2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
  3. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23(19): 4265–4274.
  4. Bell R, Verma S, Untch M, et al. Maximizing clinical benefit with trastuzumab. Semin Oncol. 2004; 31(5 Suppl 10): 35–44.
  5. Papaldo P, Fabi A, Ferretti G, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol. 2006; 17(4): 630–636.
  6. von Minckwitz G, Zielinski C, Maarteense E, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05). Journal of Clinical Oncology. 2008; 26(15_suppl): 1025–1025.
  7. Yamamoto D, Iwase S, Kitamura K, et al. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol. 2008; 61(3): 509–514.
  8. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007; 25(25): 3853–3858.
  9. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005; 6(5): 425–432.
  10. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004; 5(2): 142–147.
  11. Gelman KA, Fumleau P, Verma S, et al. Result of a phase II trial of trastuzumab and partuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy. . Proc. Am. Soc. Clin. Oncol. 2008; 26: 47s. abstract 1026.
  12. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23(23): 5305–5313.
  13. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Journal of Clinical Oncology. 2008; 26(15_suppl): 1015–1015.
  14. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112(3): 533–543.
  15. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26): 2733–2743.
  16. Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep. 2008; 10(1): 10–17.
  17. Venturini M, Paridaens R, Rossner D, et al. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology. 2007; 72(1-2): 51–57.
  18. Osako T, Ito Y, Takahashi S, et al. Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori. 2007; 93(2): 129–132.
  19. Siva M, Correa P, Skaria S, et al. Capecitabine in advanced breast cancer: Predictive factors for response. Journal of Clinical Oncology. 2008; 26(15_suppl): 1126–1126.
  20. Di Costanzo F, Gasperoni S, Papaldo P, et al. Gruppo Oncologico Italiano di Ricerca clinica, Gruppo Oncologico del Lazio. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. Ann Oncol. 2006; 17(1): 79–84.
  21. O'Shaughnessy JA, Blum JL. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer. Clin Breast Cancer. 2006; 7(1): 42–50.
  22. Benekli M, Yildiz R, Uner A, et al. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology. 2007; 72(5-6): 308–313.
  23. Estévez LG, Batista N, Sánchez-Rovira P, et al. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2008; 8(2): 149–154.
  24. Massacesi C, La Cesa A, Marcucci F, et al. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology. 2006; 70(4): 294–300.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl